54
Participants
Start Date
March 31, 2021
Primary Completion Date
April 13, 2022
Study Completion Date
April 13, 2022
Remdesivir
RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
Bronx-Lebanon Hospital Center (Site #: 5114), The Bronx
Stony Brook University Medical Center (Site #: 5040), Stony Brook
Johns Hopkins University NICHD CRS (Site #: 5092), Baltimore
Emory University School of Medicine (Site #: 5030), Atlanta
Pediatric Perinatal HIV Clinical Trials Unit (Site #: 5127), Miami
Rush University Cook County Hospital NICHD CRS (Site #: 5083), Chicago
Lurie Children's Hospital of Chicago (LCH) CRS (Site #: 4001), Chicago
Texas Children's Hospital (Site #: 5128), Houston
David Geffen School of Medicine at UCLA (Site #: 5112), Los Angeles
Childrens Hospital (U. Colorado, Denver) NICHD CRS (Site #: 5052), Denver
Collaborators (1)
Gilead Sciences
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH